Literature DB >> 23817331

Adult malaria chemoprophylaxis prescribing patterns in the military health system from 2007-2011.

Colleen M Kersgard1, Patrick W Hickey.   

Abstract

The Military Health System (MHS), with 9.7 million beneficiaries, represents an enormous pool of potential travelers requiring malaria prevention measures. A systematic search of the MHS electronic pharmacy record was performed for prescriptions of atovaquone-proguanil (AP), chloroquine (CQ), doxycycline (DC), mefloquine (MQ), primaquine (PQ) to adult patients from 2007 through 2011. Over 1,000,000 were identified, including 161,341 primary prophylaxis prescriptions originating from civilian facilities. Military facility prescription volume rose from 50,128 (PQ < 1%, AP 4%, CQ 6%, DC 53%, MQ 36%) in 2007 to 166,649 (PQ < 1%, AP 3%, CQ < 1%, DC 94%, MQ 2%) in 2011. Mefloquine use diminished in all clinics over time. The majority of military facility prescriptions originated from primary care clinics (83%); primary care clinics predominantly and increasingly prescribed DC, whereas specialty travel clinics predominantly and increasingly prescribed AP. Prescribing patterns in the MHS varied by time, practice setting, beneficiary status, and provider specialty. These changes, including among non-active duty military patients, are temporally associated with policy changes intended for the active duty force.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817331      PMCID: PMC3741255          DOI: 10.4269/ajtmh.13-0013

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  5 in total

1.  Trends in antimalarial drugs prescribed in New Zealand 1993 to 1998.

Authors:  Peter A Leggat; John L Heydon
Journal:  J Travel Med       Date:  2002 May-Jun       Impact factor: 8.490

2.  Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011.

Authors:  Regina C LaRocque; Sowmya R Rao; Jennifer Lee; Vernon Ansdell; Johnnie A Yates; Brian S Schwartz; Mark Knouse; John Cahill; Stefan Hagmann; Joseph Vinetz; Bradley A Connor; Jeffery A Goad; Alawode Oladele; Salvador Alvarez; William Stauffer; Patricia Walker; Phyllis Kozarsky; Carlos Franco-Paredes; Roberta Dismukes; Jessica Rosen; Noreen A Hynes; Frederique Jacquerioz; Susan McLellan; Devon Hale; Theresa Sofarelli; David Schoenfeld; Nina Marano; Gary Brunette; Emily S Jentes; Emad Yanni; Mark J Sotir; Edward T Ryan
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

3.  Malaria in U.S. military forces: a description of deployment exposures from 2003 through 2005.

Authors:  Paul Ciminera; John Brundage
Journal:  Am J Trop Med Hyg       Date:  2007-02       Impact factor: 2.345

4.  Trends in antimalarial prescriptions in Australia, 2005 to 2009.

Authors:  Peter A Leggat
Journal:  J Travel Med       Date:  2012-12       Impact factor: 8.490

5.  Trends in malaria chemoprophylaxis prescription in South Africa 1994 to 2000.

Authors:  Peter A Leggat; David N Dürrheim; Lucille Blumberg
Journal:  J Travel Med       Date:  2002 Nov-Dec       Impact factor: 8.490

  5 in total
  9 in total

1.  Nightmares in United States Military Personnel Are Multifactorial and Require Further Study.

Authors:  Jennifer L Creamer; Matthew S Brock; Vincent Mysliwiec
Journal:  J Clin Sleep Med       Date:  2018-07-15       Impact factor: 4.062

2.  Approval of Tafenoquine for Malaria Chemoprophylaxis.

Authors:  Jonathan D Berman
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

3.  Deployment Infectious Disease Threats: IDCRP Initiatives and Vision Forward.

Authors:  Tahaniyat Lalani; Jamie Fraser; Mark S Riddle; Ramiro L Gutierrez; Patrick W Hickey; David R Tribble
Journal:  Mil Med       Date:  2019-11-01       Impact factor: 1.437

4.  Safety, Tolerability, and Compliance with Long-Term Antimalarial Chemoprophylaxis in American Soldiers in Afghanistan.

Authors:  David L Saunders; Eric Garges; Jessica E Manning; Kent Bennett; Sarah Schaffer; Andrew J Kosmowski; Alan J Magill
Journal:  Am J Trop Med Hyg       Date:  2015-06-29       Impact factor: 2.345

5.  Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.

Authors:  Remington L Nevin
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-04-05       Impact factor: 4.077

6.  Prolonged Neuropsychiatric Symptoms in a Military Service Member Exposed to Mefloquine.

Authors:  Jeffrey Livezey; Thomas Oliver; Louis Cantilena
Journal:  Drug Saf Case Rep       Date:  2016-12

7.  Deployment and Travel Medicine Knowledge, Attitudes, Practices, and Outcomes Study (KAPOS): Malaria Chemoprophylaxis Prescription Patterns in the Military Health System.

Authors:  Patrick W Hickey; Indrani Mitra; Jamie Fraser; David Brett-Major; Mark S Riddle; David R Tribble
Journal:  Am J Trop Med Hyg       Date:  2020-04-23       Impact factor: 2.345

Review 8.  Rational Risk-Benefit Decision-Making in the Setting of Military Mefloquine Policy.

Authors:  Remington L Nevin
Journal:  J Parasitol Res       Date:  2015-10-22

9.  Compliance with preventive measures against malaria of personnel treated in the centre of international vaccination of the Minister of Defence (Spain).

Authors:  M J Ajejas Bazán; C Fuentes Mora
Journal:  Rev Esp Quimioter       Date:  2020-01-22       Impact factor: 1.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.